Chuen Yan Leung is a healthcare investor based in China. He is the co-founder of Silver Dart Capital and the Vice Chairman of the Hong Kong Biotechnology Organization. Previously he was an investment professional at the private equity group EQT, and lead scientist at Procella therapeutics. Chuen Yan obtained his PhD in developmental biology from the University of Cambridge, and did postdoctoral research in stem cells at the Karolinska Institute.
东立创新基金（美元）/ 创东方东立基金（人民币）创始及执行事务合伙人
• 香港东立创新美元基金和QFLP人民币基金–创东方东立基金主要投资方向为新科技，新材料和生物医药领域。
• 曾经在香港多年担任家族办公室的负责人，参与数亿美元海外并购项目和香港主板上市公司的收购与管理，并与多家国际著名投资银
行一起管理家族办公室的海外投资和全球资产配置等。历来参与的并购项目包括四季酒店，高尔夫球场，国际知名饮料公司等。
Mr. Liu is now the Managing Director of the CR CP Life Science Fund, whose shareholders, CR Group and CP Group are on the Fortune Global 500 List. Before that, Mr. Liu was the Business Director of the Strategic Management Department at CR Group, responsible for strategic research and project investment in life science and technology; and as Senior Director of China Resources Pharmaceutical Group Co., Ltd. (HK: 03320), responsible for business development and international cooperation. He has also served as the Senior Director of China Resources Pharmaceutical Business Group, the General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., the Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and the COO of Zhoulin Bio-spectrum Technology Co., Ltd. Prior to 2004, Mr. Liu was a pharmacy manager at CVS Group in the United States, and worked at the New York Healthcare Group as a clinical pharmacist.
Professor Chau has over 30-year extensive experience in venture development and investment in the Asian Pacific region. He is the Founding Chairman of PAVD (http://pavd.info), a non-profit oriented platform with over 80 active angels, super-angels, venture capitalists and private equity investors. In addition, he is in the Board of several technology ventures and listed companies. Academia wise, he is adjunct professor in the CUHK Business School and Shenzhen Finance Institute, teaching courses covering venture capital & private equity, entrepreneurship, fundraising, technology commercialization in EMBA, MBA and MBM programs. He is also a Specialist of the Hong Kong Council for Accreditation of Academic and Vocational Qualifications.
Prior to the current engagements, he was professor of practice in entrepreneurship in the CUHK Business School, adjunct professor in the NUS Business School, professor in the Asia University (Taiwan), the Program Director of the PAVD-RAIN (Round-A-INvestors) Program and the Curriculum Director of the Protégé VC Training Program in Singapore Management University. He holds an applied mathematics degree, a law degree, a master degree and a doctorate degree in business administration, and is a fellow member of The Association of Chartered Certified Accountants of the United Kingdom.
Prof. Tin-Lap Lee is an Associate Professor in the School of Biomedical Sciences, Faculty of Medicine at the Chinese University of Hong Kong. Before joining CUHK in 2011, he was a Staff Scientist at the Laboratory of Clinical Genomics, National Institutes of Child Health and Human Development (NICHD) at National Institutes of Health (NIH) in the United States and Project Coordinator at National Center for Biotechnology Information (NCBI).
Prof. Lee is a Hong Kong native. He obtained his undergraduate degree in molecular biology at the Hong Kong University of Science and Technology in 1997, and went on to obtain his Ph.D. in anatomical and cellular pathology at the Chinese University of Hong Kong. In 2001, he was invited to serve as a Visiting Fellow at National Institute of Deafness and Communication Disorder, National Institutes of Health in 2001 to study the molecular and genome biology of head and neck cancer.
Recognizing that a revolution was beginning in genome biology, he pursued studying bioinformatics at National Institute of Bioinformatics and became a Certified Bioinformatics Specialist in 2002, and continue his new scientific adventure in Laboratory of Clinical Genomics, National Institutes of Child Health and Human Development (NICHD) in 2004 to decode the regulatory mechanisms in developmental biology by using male germ cell and tumor models.
Prof. Lee has made a number of accomplishments in molecular and genome biology. He invented the first non-invasive method to detect epigenetic alterations in gastric cancer patients and led to prestigious Scholar-in-Training Award conferred by American Association for Cancer Research in 2001. He also discovered of p53 and NF-Kappab as the key segregating factors for molecular differentiation of head and neck cancer, which was featured on the cover of Clinical Cancer Research. His achievement in bioinformatics revolutionized dynamic analysis of Serial Analysis of Gene Expression (SAGE) data for revealing novel regulatory targets and mechanisms in male germ cell and gonad development. The work was featured on the cover of Genomics and was recognized by National Institutes of Health by prestigious NIH Merit Award in 2005 and The Fellows Award for Research Excellence in 2006. His research performance has also been recognized by Government Employee Performance Awards. He is the author of 63 publications in peer-reviewed journals with more than 1500 citations, and 70 meeting abstracts in national scientific meetings. He has served as government panel member in the genome science policy study, members in various scientific societies and mentor in undergraduate and post-graduate research programs.
A translational biomedical engineer with a strong background in business development and investments, Charles’s vision is in bringing about a vibrant healthcare innovation and investment ecosystem in the HK Greater Bay Area. He obtained his PhD from Johns Hopkins University, BS from University of California, Berkeley, and his scientific expertise interfaces across biomedical engineering, regenerative medicine, interventional radiology, and materials science. He is also experienced in research commercialization and in MNC pharma product development and medical affairs. He co-founded Incando Therapeutics to bring innovative therapeutic technologies to the clinical stage and targeting difficult to treat diseases including recurrent cancer and neurodegenerative diseases. On the business front, Charles heads Ryoden Medical Holdings where he oversees healthcare venture investments for his family office, advises angel investors and startups, and actively engages in policy discussions in support of biomedical innovations and youth talent development.
Charles is an Adjunct Professor of Biomedical Sciences, Industrial Advisor of Biomedical Engineering, 30th Anniversary Steering Committee Member, and HK Tech 300 Selection Panelist at the City University of Hong Kong, vice president of the BIOHK international biotechnology conventions, board member of two biotechnology companies, council advisor to the Asian Fund for Cancer Research, member of the Hong Kong Professionals and Senior Executives Association (HKPASEA), and director of several retail, food & beverage, and real estate businesses. He was awarded the Outstanding Young Entrepreneur Award and Best Sci-Tech Innovation Project in 2023 by the Guangdong-HK-Macao Bay Area Entrepreneurs Union and the Chinese General Chamber of Commerce (“CGCC”) in Hong Kong.
Mr. Wong Tat Tung, MH, JP has over 25 years’ business experience in the field of asset management and investment. He was appointed as the Vice President of Credit Suisse Privilege Limited in Hong Kong in 1998 and has later become a responsible officer of asset management for other financial institutions for many years. Mr. Wong has dedicated many efforts in developing business related to health management in recent years because he believes that being healthy and wealthy are the pursuit of most people. The founding of H&W Group aims at devloping advanced laboratory testing, medical and health management services. Mr. Wong is currently the Chairman of Young+ Wellness and KK WeCheck Limited.
Besides being an entrepreneur, Mr. Wong has also been a keen participant of public welfare and social service over the years. He has held office in numerous non-profit organizations, including:
Chairperson of the 33rd Term Board of Directors of Yan Oi Tong
Vice Chairman of Federation of Hong Kong Guangdong Community Organizations
Deputy Director General of Kowloon Federation of Associations
Executive Vice Chairmen and Founder of Hong Kong Guangdong Youth Association
Management Committee Member of Wuyi University
Dr. Wong was appointed as the Chief Technology Officer of New A Innovation Limited in June 2007 and currently Dr. Wong serves an honorary professor at the Department of Biochemistry of Chinese University of Hong Kong.
From 2002 to 2007, Dr. Wong was the Board Director and Chief Executive Officer of Advantek Biologics (HK) Limited. He has 40 years of experience in the development of protein therapeutics in Biotechnology industry.
During his tenure as Acting Director at the New England Enzyme Center and Associate Professor at Tufts Medical School of Boston, Dr. Wong was responsible for the preparations of hundreds of biologics. Dr. Wong then co-founded Biopure Corporation (NASDAQ: BPUR), where he served as CTO and Senior Vice President. At Biopure, Dr. Wong was responsible for the development of Cephalosporin antibiotics and Hemoglobin-based oxygen carriers (artificial blood): Hemopure? and Oxyglobin?, as well as the strategic business ventures in the US and the Far East. Dr. Wong has also held a series of patents and been a licensor to a number of world-leading companies such as Roche (SWX: RO) and Teva (NASDAQ: TEVA).
In 1992, the Executive Yuan of ROC named him Model of Overseas Chinese Young Entrepreneur. In 2001, Bunker Hill Community College of Boston, Massachusetts awarded Dr. Wong a President’s Distinguished Service Award for his extraordinary commitment for higher education in the Boston Asian community.
晶准醫學集團首席執行官(腫瘤精準醫學)
團結香港基金顧問
InvestHK醫療保健顧問
HKBIO副主席
香港應用科技研究院董事會成員
劉先生是一位具有豐富業務經驗的運營高管。他在私募股權和風險投資公司擔任多年，運營醫療保健和製藥行業的投資組合公司。 劉先生目前是晶准醫學的首席執行官，該公司是液體活檢技術在癌症篩查和精準診斷領域的領導者。劉先生之前擔任過多個高管職位，包括Basebit Technologies總裁、CW Data Technologies首席執行官和Ilumi Health首席執行官。 劉先生曾任IQVIA的亞太地區和中國區總裁（前身為IMS Health）。劉先生負責管理整個亞太地區的數據分析、數字解決方案以及商業和咨詢業務。他負責管理包括中國、澳大利亞、印度、韓國、新西蘭、香港、台灣、越南、印度尼西亞、菲律賓、泰國、新加坡、馬來西亞、台灣、孟加拉國、斯里蘭卡和巴基斯坦在內的17個國家/地區的業務。劉先生在默克和UCB Pharma等跨國公司擔任高管和領導職位。他還在私募股權公司TPG擔任多年運營人員，負責運營TPG的投資組合公司，包括IMS和Moksha8。 劉先生的關注領域是醫療產品的上市和商業化，包括監管批准、定價、顧客獲取、市場營銷和銷售執行。他成功管理和推出了高血壓、動脈硬化、抗癲癇藥物、關節炎、抗組織胺、骨質疏鬆症和糖尿病等重要治療領域的產品。他在生命科學領域的交易、投資、合資企業和併購方面也具有豐富的經驗。
Dr. Gina Jiang is the Managing Director of the Hong Kong Institute of Biotechnology and the Head of Technology Integration and Application at the Chinese University of Hong Kong, where she leads the establishment of the Advanced Therapy Products (ATP) GMP Centre, the modernisation of Proprietary Chinese Medicine (pCM) manufacturing, the expansion of the institute’s GMP capabilities and capacities, and trainings of GMP talents.
A medical entrepreneur that sits at the intersection of medicine, design, and technology, Dr. Jiang has built a number of med tech startups in Silicon Valley and Taipei, including FGMi, Inc., which focuses on analysing patients’ clinical needs and overall patient journeys to accelerate beachside researches to bedside applications.
Chinese 
English